Debora Peralta

A member of the GlycoMimetics management team since February 2023, Debora has extensive global and US commercial pharmaceutical and biotech experience, highlighted by more than 17 product launches, and in-depth knowledge of the hematology, oncology and rare disease therapeutic areas.

Before joining GlycoMimetics, Debora was Rare Disease, VP Franchise Head, for Ipsen. In that role, she hired a commercial team that would represent this new area of investment and focus for the company, developed and concluded the launch strategy and commercialization plans for palovarotene, and identified and developed new commercial opportunities.

Debora spent 16 years of her career at Novartis, where she developed professionally through roles of increasing responsibility in the hematology, oncology and rare disease therapeutic areas. Among those roles, she was Senior Marketing Director, U.S. Hematology, for which she led the team supporting the simultaneous Rydapt® launch in two indications (Acute Myeloid Leukemia and Advanced Systemic Mastocytosis); Executive Director, Global Hematology Franchise, for which she led and managed the launch preparation for a sickle cell disease product; and Executive Director, Rare Diseases, Global Solid Tumor Franchise.

In addition to a strong strategy skillset and the ability to navigate complex commercial scenarios, Debora has extensive experience leading multidisciplinary teams and a deep understanding of what it takes to bring products to market as well as pipeline management.

Debora holds a Bachelor of Science in Biomedicine from Mogi das Cruzes University, Brazil, as well as a post-graduate degree in marketing and MBA in marketing administration from ESPM Marketing College in Sao Paulo, Brazil. She is fluent in English, Portuguese, and Spanish.